Philip Rosenthal’s work centers on three major areas, all focused on malaria, one of the most significant infectious diseases affecting humans. First, he investigates the basic biology of malaria parasites, examining the biochemical properties and biological roles of parasite proteases as well as the mechanisms of action of novel antimalarial agents. Second, in collaboration with industry and academic partners, he pursues drug discovery efforts, evaluating protease inhibitors, oxaboroles, and other compounds as potential antimalarial drugs. Third, he conducts malaria research in Africa, leading translational and laboratory studies at UCSF and in Uganda and Burkina Faso to assess antimalarial drug efficacy and resistance, explore the molecular epidemiology of malaria, and analyze how host and parasite genetic polymorphisms influence treatment outcomes. His work also examines antimalarial pharmacokinetics and pharmacodynamics and related topics. A newer area of interest for Rosenthal involves using genetic tools to identify the causes of febrile illnesses in African children. In addition to his research, Rosenthal serves as Editor-in-Chief of the American Journal of Tropical Medicine and Hygiene; Chair of the Scientific Advisory Committee for the WorldWide Antimalarial Resistance Network; a member of the Scientific Board of the Infectious Diseases Data Observatory; and a member of the World Health Organization Technical Expert Group on Malaria Chemotherapy.